Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Pipeline & R&D

ALX Oncology says $147.2M should fund it past two data readouts into 2028

The US biotech's third-quarter loss was $21.8 million, and management says its balance sheet is sized to reach an EGFR-directed ADC update and a breast cancer Phase 2 result.

16 Nov 2026 · Alx Oncology Holdings Inc ALXO · Company news

ALX Oncology ended the third quarter with $147.2 million in cash and investments. The company says that is enough to run the business into the first half of 2028. The figure was published on 16 November alongside a quarterly net loss of $21.8 million. The timeframe is management's own guidance, not an independent estimate.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Alx Oncology Holdings Inc ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pipeline & R&DAll →